ESCROW AGREEMENTEscrow Agreement • September 27th, 2022 • Facible BioDiagnostics, Inc. • Services-medical laboratories • Delaware
This ESCROW AGREEMENT (this “Agreement”) dated as of this 4th day of January 2022 by and among Facible BioDiagnostics, Inc., a Delaware corporation (the “Company”), having an address at 366 SW 5th Ave Suite 104 Meridian, ID 83642; Rialto Markets, LLC, having an address at 42 Broadway, Ste 12-129, NY, NY 10004 (“Placement Agent”), and WILMINGTON TRUST, NATIONAL ASSOCIATION (the “Escrow Agent”), with its principal corporate trust office at 99 Wood Avenue South, 10th Floor, Iselin, NJ 08830. The Company and the Placement Agent, each a “Party,” are collectively referred to as “Parties” and individually, a “Party.”
FACIBLE BIODIAGNOSTICS, INC., A DELAWARE CORPORATION CLASS A COMMON STOCK SHARES REGULATION A+ SUBSCRIPTION AGREEMENTSubscription Agreement • September 27th, 2022 • Facible BioDiagnostics, Inc. • Services-medical laboratories
Investing in securities represented by shares of Class A common stock (“Shares”) of Facible BioDiagnostics, Inc. (the “Company”) involves significant risks. This investment is suitable only for persons who can afford to lose their entire investment and such investment could be illiquid for an indefinite period of time. No public market currently exists for the Shares, and if a public market develops following this offering, it may not continue.
VOTING AGREEMENTAdoption Agreement • September 27th, 2022 • Facible BioDiagnostics, Inc. • Services-medical laboratories • Delaware
THIS VOTING AGREEMENT (this “Agreement”) is made and entered into as of [_____], 2022, by and among Facible BioDiagnostics, Inc., a Delaware corporation (the “Company”), each holder of the Series A-1 Preferred Stock, $0.001 par value per share, of the Company (“Series A-1 Preferred Stock”), Series A-2 Preferred Stock, $0.001 par value per share, of the Company (“Series A-2 Preferred Stock”), and Series A-3 Preferred Stock, $0.001 par value per share, of the Company (“Series A-3 Preferred Stock” and together with the Series A-1 Preferred Stock and Series A-2 Preferred Stock, the “Preferred Stock”), listed on Schedule A (together with any subsequent investors, or transferees, who become parties hereto as “Investors” pursuant to Sections 7.1(a) or 7.2 below, the “Investors”), and those certain stockholders who each hold Class B Common Stock, $0.001 par value per share, of the Company (“Class B Common Stock”) and an equivalent amount of Class A Common Stock, $0.001 par value per share, of
